Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC)[1][2].
Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab)[1].
Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells[2].
Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs) [2].
Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys[1].
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts[2].
| Animal Model: | Cynomolgus monkey[1] |
| Dosage: | 0.6, 6.0, and 60 mg/kg |
| Administration: | Intravenous injection (i.v.) |
| Result: | Induced > 100- fold increases in circulating concentrations of PDGF-AA. |
| Animal Model: | U118 glioma xenografts (CB17 SCID)[2] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), twice per week. |
| Result: | Produced 101% inhibition of tumor growth. |